Expanding Its Team of Regulatory Experts to Guide Biopharmaceutical Sponsors
Along the Pathway to Market Approval
December 16, 2019
January 6, 2019
Upon receiving approval from Health Canada, Antibe Therapeutics selected Veristat to immediately begin work on part one of a Phase 2B dose-ranging, efficacy study for their lead drug candidate ATB-346. The study will run in Canada and is expected to conclude in December 2018.